secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-139366
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete
------------------------------------------------------------------------------

- Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.
- Cash and equivalents $48.7M as of March 31, 2024, down from $57.4M at Dec 31, 2023.
- Phase 3 Orbit study (setrusumab) fully enrolled (158 patients); Cosmic enrolled 69 patients.
- Alvelestat SGRQ validation completed; Phase 3 protocol to be submitted to FDA in H1 2024.
- Cash guidance unchanged: funds operations into 2026; no alvelestat partnership upfront included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/0001193125-24-139366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/d787110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-139366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer